UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For
the month of August 2026
Commission
File Number: 001-42527
Basel
Medical Group Ltd
6
Napier Road,
Unit
#02-10/11 Gleneagles Medical Centre
Singapore
258499
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Explanatory
Note
On
July 23, 2026, a securities class action complaint (the “Action”) was filed in the Supreme Court of the State of New York,
County of New York, naming as defendants more than 30 publicly traded companies in the U.S., including Basel Medical Group Ltd (the “Company”),
more than 10 broker-dealer firms in the U.S. and certain other named individuals. The summons and complaint were served on the process
agent of the Company on August 5, 2026. The Company is currently reviewing the merits of such Action. The action is at an early stage
and the Company is unable to predict such contingency or estimate any likely outcome at this time.
SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS
Statements
in this current report with respect to the Company’s current plans, estimates, strategies, beliefs, and other statements that are
not historical facts are forward-looking statements about the future performance of the Company. Forward-looking statements include,
but are not limited to, those statements using words such as “believe,” “expect,” “plans,” “strategy,”
“prospects,” “forecast,” “estimate,” “project,” “anticipate,” “aim,”
“intend,” “seek,” “may,” “might,” “could,” or “should,” and words
of similar meaning in connection with a discussion of future operations, financial performance, events, or conditions. From time to time,
oral or written forward-looking statements may also be included in other materials released to the public. These statements are based
on management’s assumptions, judgments, and beliefs in light of the information currently available to it. The Company cautions
investors that a number of risks and uncertainties could cause actual results to differ materially from those discussed in the forward-looking
statements, including but not limited to, unforeseen legal, regulatory, or operational developments, and other risks contained in reports
filed by the Company with the U.S. Securities and Exchange Commission. Therefore, investors should not place undue reliance on such forward-looking
statements. Actual results may differ significantly from those set forth in the forward-looking statements. All such forward-looking
statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by the cautionary statements
and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation
to update any forward-looking statements to reflect events or circumstances after the date hereof.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
| |
Basel
Medical Group Ltd |
| |
|
|
| |
By: |
/s/
Darren Yen Feng Chhoa |
| |
Name: |
Dr.
Darren Yen Feng Chhoa |
| |
Title: |
Chief
Executive Officer |
| |
|
|
| Date:
August 10, 2026 |
|
|
